LEGN Heads Into Print With Short Squeeze Potential Intact

Legend Biotech reports today with a stock that has surged 30% in a month yet still carries short interest above 8% of the free float, an unusual combination that makes the lending market the central story heading into the number.

The borrow tension noted in October has eased slightly but has not resolved. Availability now sits at 43%, meaning roughly one share is available for every two already lent out. That is tighter than the 54% level seen a week ago and dramatically below the 135% available in late September, when the borrow market was effectively unconstrained. Short interest itself edged down 1.7% on November 6 to 8.76% of the float, continuing a covering trend from the mid-October peak near 10.8%. The options market is not adding much pressure from the other side. The put/call ratio of 0.43 is barely above its 20-day average of 0.41, well away from the 52-week high of 1.43, which means call positioning is dominant and there is no broad demand for downside protection ahead of the print. The ORTEX short score has held near 77 for a week, ranking in the 5th percentile, one of the more heavily shorted profiles in the broader universe.

The bull and bear cases orbit a single question: whether CARVYKTI can sustain momentum against a sharpening competitive threat. Bulls point to the clinical durability of the franchise, with 60.5-month median progression-free survival and over 70% of US volume now coming from second-to-fourth-line patients, plus a first adjusted-profitable quarter with collaboration profit of $326 million. Bears are focused on Gilead's anito-cel, whose PDUFA date falls on December 23, 2026, raising the concern that physicians are already warehousing patients ahead of a potential new entrant. Analyst targets cluster well above the current price. Barclays holds a $68 Overweight, RBC Capital an $56 Outperform, and Morgan Stanley a $49 Overweight, all set before or just after the Q2 print in August and October. JP Morgan sits apart at $33 Neutral, nearly in line with where the stock is trading today. The mean consensus target near $46 implies meaningful upside on paper, but the target range is unusually wide, which itself reflects genuine uncertainty about the December competitive dynamic.

Ownership concentration adds an interesting wrinkle. Genscript Biotech holds 45% of shares, limiting the actively tradable float, while FMR LLC filed an amended 13G on November 5 disclosing a stake that has fallen from 15% to 12.4%. That reduction by Fidelity is the most recent institutional movement, and it comes just days before the print. No 13D activist is on the register, so the pressure is commercial rather than governance-driven. Wikipedia attention spiked to a z-score of 4.1 in mid-October, one of the sharper retail-attention readings in the data, consistent with the stock's 30% monthly rally drawing broader interest.

Today's print tests whether CARVYKTI's commercial trajectory through Q3 is robust enough to sustain a valuation that has rerated sharply upward even as the competitive clock on anito-cel's approval ticks closer.